Literature DB >> 20842106

T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

Jiali Sun1, Gianpietro Dotti, Leslie E Huye, Aaron E Foster, Barbara Savoldo, Maria M Gramatges, David M Spencer, Cliona M Rooney.   

Abstract

Adoptive transfer of antigen-specific cytotoxic T lymphocytes has shown promise for the therapy of cancer. However, tumor-specific T cells are susceptible to diverse inhibitory signals from the tumor microenvironment. The Akt/protein kinase B plays a central role in T-cell proliferation, function, and survival and we hypothesized that expression of constitutively active Akt (caAkt) in T cells could provide resistance to many of these tumor-associated inhibitory mechanisms. caAkt expression in activated human T cells increased proliferation and cytokine production, a likely result of their sustained expression of nuclear factor-κB (NF-κB) and provided resistance to apoptosis by upregulating antiapoptotic molecules. caAkt expressing T cells (caAkt-T-cells) were also relatively resistant to suppression by and conversion into regulatory T cells (Tregs). These characteristics provided a survival advantage to T cells cocultured with tumor cells in vitro; CD3/28-stimulated T cells expressing a chimeric antigen receptor (CAR) specific for disialoganglioside (GD2) that redirected their activity to the immunosuppressive, GD2-expressing neuroblastoma cell line, LAN-1, resisted tumor-induced apoptosis when co-expressing transgenic caAkt. In conclusion, caAkt-transduced T cells showed resistance to several evasion strategies employed by tumors and may therefore enhance the antitumor activity of adoptively transferred T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20842106      PMCID: PMC2990520          DOI: 10.1038/mt.2010.185

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  An essential role for Akt1 in dendritic cell function and tumor immunotherapy.

Authors:  Dongsu Park; Natalia Lapteva; Mamatha Seethammagari; Kevin M Slawin; David M Spencer
Journal:  Nat Biotechnol       Date:  2006-12-03       Impact factor: 54.908

3.  Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner.

Authors:  Y Fujio; K Walsh
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

Review 4.  'Vive la Résistance!'--the PI3K-Akt pathway can determine target sensitivity to regulatory T cell suppression.

Authors:  Elizabeth A Wohlfert; Robert B Clark
Journal:  Trends Immunol       Date:  2007-02-27       Impact factor: 16.687

5.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Authors:  C M Rooney; C A Smith; C Y Ng; S K Loftin; J W Sixbey; Y Gan; D K Srivastava; L C Bowman; R A Krance; M K Brenner; H E Heslop
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

Review 6.  Intracellular signals of T cell costimulation.

Authors:  Jianxun Song; Fengyang Tylan Lei; Xiaofang Xiong; Rizwanul Haque
Journal:  Cell Mol Immunol       Date:  2008-08       Impact factor: 11.530

Review 7.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells.

Authors:  P D Greenberg
Journal:  Adv Immunol       Date:  1991       Impact factor: 3.543

8.  PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3.

Authors:  Ingrid Remy; Annie Montmarquette; Stephen W Michnick
Journal:  Nat Cell Biol       Date:  2004-03-28       Impact factor: 28.824

Review 9.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

10.  The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells.

Authors:  Sokol Haxhinasto; Diane Mathis; Christophe Benoist
Journal:  J Exp Med       Date:  2008-02-18       Impact factor: 14.307

View more
  42 in total

Review 1.  Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.

Authors:  Maya Suzuki; Kevin J Curran; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2015-04-01       Impact factor: 3.167

Review 2.  Genetically modified T-cell therapy for osteosarcoma.

Authors:  Christopher DeRenzo; Stephen Gottschalk
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

3.  CAR-T cells and combination therapies: What's next in the immunotherapy revolution?

Authors:  Maria C Ramello; Eric B Haura; Daniel Abate-Daga
Journal:  Pharmacol Res       Date:  2017-12-01       Impact factor: 7.658

Review 4.  Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis
Journal:  Discov Med       Date:  2013-12       Impact factor: 2.970

Review 5.  Gene-engineered T cells for cancer therapy.

Authors:  Michael H Kershaw; Jennifer A Westwood; Phillip K Darcy
Journal:  Nat Rev Cancer       Date:  2013-08       Impact factor: 60.716

Review 6.  The pharmacology of second-generation chimeric antigen receptors.

Authors:  Sjoukje J C van der Stegen; Mohamad Hamieh; Michel Sadelain
Journal:  Nat Rev Drug Discov       Date:  2015-07       Impact factor: 84.694

Review 7.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

9.  Selective inhibition of regulatory T cells by targeting the PI3K-Akt pathway.

Authors:  Rasha Abu-Eid; Raed N Samara; Laurent Ozbun; Maher Y Abdalla; Jay A Berzofsky; Kevin M Friedman; Mikayel Mkrtichyan; Samir N Khleif
Journal:  Cancer Immunol Res       Date:  2014-07-30       Impact factor: 11.151

Review 10.  Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.

Authors:  Valentina Hoyos; Barbara Savoldo; Gianpietro Dotti
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.